ILMN Illumina Inc

$0.00 (0.00%)

ILMN Stock Analysis Overview

What this means: InvestorsObserver gives Illumina Inc (ILMN) an overall rank of 50, which is below average. Illumina Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 50 means that 50% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Illumina Inc (ILMN) Analyst Forecast

Next 12 months ➝Current Price$355.6652-week High$404.2052-week Low$196.78MEAN$332.07-6.63%HIGH$390.00+9.66%LOW$220.00-38.14%
  • Last Price$355.66
  • Previous Close$355.66
  • Change $0.00
  • Open$343.00
  • Volume4,266,300
  • Avg. Volume (100-day)1,089,730
  • Market Capitalization$52B
  • Days Range $343.00 - $360.69
  • 52-week Range $196.78 - $404.20
  • Dividend Yield
  • Ex. Dividend Date
  • P-E63.1
  • EPS6.35
  • Earnings Date11/04/2020
  • SectorHealthcare
  • IndustryDiagnostics & Research
  • Avg. Analyst Rec.
  • Beta1.792
  • PEG Ratio5.93
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (73% of 2019 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 17% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.